Michael Triplett, Ph.D.
Co-founder & Board Co-Chair
Michael Triplett, Ph.D. is an accomplished entrepreneur and veteran start-up executive. Dr. Triplett is passionate about translating world-class science and technology into transformative businesses, products, and capabilities that enhance human health, American competitiveness, and economic opportunity. Prior to Clarametyx, Dr. Triplett co-founded and served as President and CEO of Myonexus Therapeutics, a clinical stage gene therapy company developing first-ever treatments for limb-girdle muscular dystrophies, which was acquired by Sarepta Therapeutics in April 2019. He is prior CEO of N8 Medical, Inc., and previously held leadership roles spanning business development, innovation, new ventures, and strategy for the Health & Life Sciences Global Business at Battelle. He received his bachelor’s degree and Ph.D., both in Chemical Engineering, from The Ohio State University.